Why NDAQ Could Outperform CME Stock
NDAQ is CME’s peer in Financial Exchanges & Data industry that has:
1) Lower valuation (P/OpInc) compared to CME stock
2) But higher revenue and operating income growth
This disconnect between valuation and performance could mean that you are better off buying NDAQ stock vs. CME stock
Individual stocks swing but a balanced asset allocation doesn’t. Trefis’ Boston-based, wealth management partner blends strategy and discipline to smooth out market noise.
- Pay Less, Gain More: NDAQ Tops CME Stock
- Pay Less, Gain More: NDAQ Tops CME Stock
- Why NDAQ Could Outperform CME Stock
- Buy Or Sell CME Group Stock Ahead Of Earnings?
- With MCO Down 5.8% in a Day, Is It Time to Compare It Against CME?
- Why Isn’t CME Group Stock Performance Reflecting Its Record Revenues, Improving Margins?
Key Metrics Compared
| Metric | CME | NDAQ |
|---|---|---|
| P/OpInc* | 24.7x | 21.5x |
| LTM OpInc Growth | 8.0% | 22.9% |
| 3Y Avg OpInc Growth | 11.8% | 13.0% |
| LTM Revenue Growth | 5.8% | 16.4% |
| 3Y Avg Revenue Growth | 8.9% | 10.5% |
OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio
But do these numbers tell the full story? Read Buy or Sell CME Stock to see if CME still has an edge that holds up under the hood. As a quick background, CME (CME) provides global futures and options trading markets, clearing, settling, and guaranteeing services for professional traders, institutions, investors, corporations, and governments.
This is just one approach to evaluate investments. Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risk while giving upside exposure
Is The Mismatch In Stock Price Temporary
One way to check if CME stock is expensive now versus the other tickers would be to see how these metrics compared across companies exactly a year ago. Specifically, if there has been a marked reversal in the trend for CME in the last 12 months, then there is a chance that the current mismatch is likely to reverse. On the other hand, a persistent underperformance in revenue and operating income growth for CME would reinforce the conclusion that the stock is expensive compared to its peers, but may not revert soon
Key Metrics Compared 1 Yr Prior
| Metric | CME | NDAQ |
|---|---|---|
| P/OpInc* | 18.4x | 20.3x |
| LTM OpInc Growth | 15.5% | 17.9% |
| 3Y Avg OpInc Growth | 13.8% | 11.8% |
| LTM Revenue Growth | 11.2% | 23.6% |
| 3Y Avg Revenue Growth | 10.0% | 11.5% |
OpInc = Operating Income
Additional Metrics To Consider
| Metric | CME | NDAQ |
|---|---|---|
| P/S | 16.0x | 6.1x |
| Market Cap (Current) | $ 102.5 Bil | $ 49.9 Bil |
| LTM Revenue | $ 6.40 Bil | $ 8.17 Bil |
| LTM Opinc | $ 4.16 Bil | $ 2.32 Bil |
| LTM Op Margin | 65.0% | 28.4% |
OpInc = Operating Income
Alternate buying based on valuation, while attractive, needs to be evaluated carefully from multiple angles. Such multi-factor analysis is exactly how we construct Trefis portfolio strategies. If you want upside with a smoother ride than an individual stock, consider the High Quality portfolio, which has outperformed the its benchmark – a combination of S&P 500, Russell, and S&P midcap index.